secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001193125-25-072869
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics appoints Leone Patterson to Board as Audit Committee Chair
-------------------------------------------------------------------------------

- Leone Patterson elected Class III director effective April 3, 2025; term expires at 2026 annual meeting.
- Patterson named Chair of Audit Committee; committee now includes Patterson, Adamis, and Jovan-Embiricos.
- No arrangements or family relationships with other directors; standard indemnification agreement to be entered.
- Company expects to adopt new non-employee director compensation program; Patterson will receive compensation once adopted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525072869/0001193125-25-072869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525072869/d891759d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-072869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer